Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasDiseaseNHL, B-Cell Type, Plasmoblastic LymphomaSubgroupICD10C83.3MeSHPlasmablastic LymphomaSequenceChemotherapyChemo-substanceBortezomibCyclophosphamideDoxorubicinEtoposideMethotrexateNaCl 0.9%PrednisoloneVincristineChemo-substanceBortezomibCyclophosphamideDoxorubicinEtoposideMethotrexateNaCl 0.9%PrednisoloneVincristineChemo-substanceBortezomibCyclophosphamideDoxorubicinEtoposideMethotrexateNaCl 0.9%PrednisoloneVincristineChemo-substanceBortezomibCyclophosphamideDoxorubicinEtoposideMethotrexateNaCl 0.9%PrednisoloneVincristineNo. Substances8 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleGranisetronMesnaPegfilgrastimSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleGranisetronMesnaPegfilgrastimSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleGranisetronMesnaPegfilgrastimSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleGranisetronMesnaPegfilgrastimNo. Substances7Protocol classificationTherapy classificationcurrent standardIntensityDose intensifiedTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeuropathyThrombocytopenia below 50 000/µl only studiesPublicationAuthorCastillo JDiseaseplasmoblastisches Lymphom, mit und ohne HIV-Infektion, ECOG 0OriginDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MAProtocols in Revision 1 protocol foundProtocols under revision.DA- EPOCH/BORT - Bortezomib 1.3 / Etoposide 50 / Prednisolone 120 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, Plasmoblastic Lymphoma (PID2037 V1.0)
